中国乳腺癌重要基础转化研究——进展与展望

卢愚风; 王晗; 谢亦璠; 江一舟; 邵志敏

doi:10.19401/j.cnki.1007-3639.2025.02.001

您当前的位置：

首页 >

文章列表页 >

中国乳腺癌重要基础转化研究——进展与展望

专家述评 | 更新时间：2025-12-31

- 中国乳腺癌重要基础转化研究——进展与展望
- Significant fundamental translational research on breast cancer in China: progress and prospects
- 中国癌症杂志 2025年35卷第2期页码：143-153
- 作者机构：
  
  复旦大学附属肿瘤医院乳腺外科/复旦大学乳腺癌研究所，复旦大学上海医学院肿瘤学系，上海 200032
- 作者简介：
  
  [ "卢愚风（ORCID: 0009-0005-7396-4702），复旦大学附属肿瘤医院博士研究生。" ]
  [ "邵志敏，主任医师，教授，首批教育部长江学者特聘教授，国家杰出青年科学基金项目获得者，复旦大学特聘教授，复旦大学肿瘤研究所所长，复旦大学乳腺癌研究所所长，复旦大学附属肿瘤医院大外科主任兼乳腺外科主任。担任中华医学会肿瘤学分会副主任委员、中国抗癌协会乳腺癌专业委员会名誉主任委员、中国抗癌协会肿瘤靶向治疗专业委员会主任委员、第八届亚洲乳腺癌协会主席，连续四届担任圣加仑国际乳腺癌大会专家团成员。主要从事乳腺癌的临床和基础研究，建立适合中国人群的早期筛查和诊疗流程，确立乳腺癌“复旦分型”和精准治疗策略，开展临床试验改善患者预后。在JAMA、BMJ、Cancer Cell、Nature Genetics、Cell Metabolism、Lancet Oncology、Journal of Clinical Oncology、JAMA Oncology等重要期刊上发表多篇论文，主编专著10部。先后获得国家科技进步二等奖，教育部科技进步一、二等奖，卫健委科技进步一等奖，上海市科技进步一、二、三等奖，领衔团队入选教育部创新团队。先后主持国家自然科学基金重大项目、国家自然科学基金专项项目、国家卫健委临床重点项目等国家级及省部级项目。" ]
- 基金信息：
  
  国家自然科学基金(U24A20736);国家自然科学基金(82425044)
- DOI：10.19401/j.cnki.1007-3639.2025.02.001
  中图分类号： R737.9
- 收稿：2024-12-30，
  
  修回：2025-01-24，
  
  纸质出版：2025-02-28
- 稿件说明：
移动端阅览
卢愚风, 王晗, 谢亦璠, 等. 中国乳腺癌重要基础转化研究——进展与展望[J]. 中国癌症杂志, 2025,35(2):143-153.

Yufeng LU, Han WANG, Yifan XIE, et al. Significant fundamental translational research on breast cancer in China: progress and prospects[J]. China Oncology, 2025, 35(2): 143-153.
卢愚风, 王晗, 谢亦璠, 等. 中国乳腺癌重要基础转化研究——进展与展望[J]. 中国癌症杂志, 2025,35(2):143-153. DOI： 10.19401/j.cnki.1007-3639.2025.02.001.

Yufeng LU, Han WANG, Yifan XIE, et al. Significant fundamental translational research on breast cancer in China: progress and prospects[J]. China Oncology, 2025, 35(2): 143-153. DOI： 10.19401/j.cnki.1007-3639.2025.02.001.

摘要

乳腺癌作为威胁中国女性健康的常见恶性肿瘤之一，其发病率和死亡率正持续攀升。面对这一严峻形势，迫切需要通过基础转化研究来优化治疗方案，以应对当前治疗中存在的挑战。本文综述中国近5年在乳腺癌基础转化研究领域的关键进展，旨在为乳腺癌的精准治疗提供科学依据和新方向。研究涵盖乳腺癌的分子分型、生物标志物发掘、耐药机制探索、精准治疗策略优化以及新靶点的鉴别等多个方面。在分子分型方面，研究者通过深入分析乳腺癌亚型，揭示了不同亚型在治疗响应上的显著差异，并针对各亚型提出了特定的治疗策略，为实现个体化治疗奠定了理论基础。生物标志物的发掘为患者选定合适的治疗方案提供了重要依据。研究显示，利用液体活检和蛋白质组学技术，已发现多个有前景的生物标志物，为乳腺癌的早期诊断和预后评估带来了新希望。在耐药机制的研究中，研究者们揭示了内分泌治疗和人表皮生长因子受体2（human epidermal growth factor receptor 2，HER2）靶向治疗耐药的分子机制，并提出了逆转耐药的潜在策略，为提升治疗效果开辟了新途径。在免疫治疗和靶向治疗领域，新靶点和生物标志物的识别为乳腺癌治疗提供了新的视角。基于对肿瘤异质性的深入理解，科研人员通过多组学分析不断优化精准治疗策略，为乳腺癌患者提供了更为个性化的治疗方案。同时，新技术的应用也在持续推动乳腺癌精准治疗的发展。例如，人工智能技术在乳腺癌的早期筛查、诊断、疗效评估及预后预测中展现出巨大潜力。另一方面，通过纳米技术开发新型药物递送系统，提高了药物的靶向性和疗效。此外，水凝胶贴片技术和肿瘤疫苗的研究为乳腺癌的治疗提供了新策略。总体而言，中国在乳腺癌基础转化研究领域取得了显著成就，这些研究成果不仅加深了我们对乳腺癌分子机制的理解，也为未来治疗策略的发展带来希望。随着多学科融合的推进和新兴技术的应用，精准治疗有望为乳腺癌患者带来更多获益。

Abstract

Breast cancer is the most prevalent malignant tumor that poses a threat to women's health in China

with incidence and mortality rates persistently increasing. Given this critical situation

there is an urgent need to optimize therapeutic options through basic translational research to address current treatment challenges. This article provided a comprehensive overview of the significant advancements in fundamental translational breast cancer research in China over the past five years

aiming to provide a scientific basis and new directions for precision treatment of breast cancer. This research encompasses a range of subjects

including molecular typing

biomarker identification

exploration of drug resistance mechanisms

optimization of precision treatment strategies

and identification of new targets in breast cancer. In the domain of molecular typing

researchers have revealed substantial disparities in treatment responses among distinct subtypes of breast cancer through in-depth analysis. This has led to the proposal of specific therapeutic strategies for each subtype

thereby establishing a robust theoretical foundation for individualized treatment approaches. The identification of biomarkers plays a pivotal role in selecting appropriate treatment options for patients. Recent research advancements have demonstrated the potential of liquid biopsy and proteomics technologies in uncovering promising biomarkers

offering novel prospects for the early diagnosis and prognostic assessment of breast cancer. In the investigation of resistance mechanisms

researchers have elucidated the molecular underpinnings of resistance to endocrine therapy and human epidermal growth factor receptor 2 (HER2)-targeted therapy and proposed potential strategies to overcome resistance. This has paved the way for novel approaches to enhance therapeutic efficacy. In the context of immunotherapy and targeted therapies

the discernment of novel targets and biomarkers has facilitated novel perspectives on breast cancer treatment. Based on advanced comprehension of tumor heterogeneity

researchers constantly optimize precision treatment strategies through multiomics analysis

thus offering patients with breast cancer enhanced personalized treatment options. Concurrently

the implementation of novel technologies has been instrumental in facilitating the advancement of precision treatment for breast cancer. For instance

the application of artificial intelligence technology has demonstrated considerable potential in the early screening

diagnosis

efficacy assessment and prognosis prediction of breast cancer. Conversely

the advent of innovative drug delivery systems facilitated by nanotechnology has led to enhanced targeting and efficacy of pharmaceutical agents. Furthermore

research into hydrogel patch technology and tumor vaccines has yielded novel strategies for the treatment of breast cancer. Overall

China has accomplished remarkable achievements in the field of basic translational research on breast cancer. These findings not only enhance our understanding of the molecular mechanisms of breast cancer

but also provide new directions and hope for the development of future therapeutic strategies. With the advancement of multidisciplinary integration and the application of new emerging technologies

precision therapy is expected to provide more benefits to breast cancer patients.

关键词

Keywords

references

HAN B F , ZHENG R S , ZENG H M , et al . Cancer incidence and mortality in China, 2022 [J ] . J Natl Cancer Cent , 2024 , 4 ( 1 ): 47 - 53 .

PEROU C M , SØRLIE T , EISEN M B , et al . Molecular portraits of human breast tumours [J ] . Nature , 2000 , 406 ( 6797 ): 747 - 752 .

HUPPERT L A , GUMUSAY O , IDOSSA D , et al . Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer [J ] . CA Cancer J Clin , 2023 , 73 ( 5 ): 480 - 515 .

中国抗癌协会乳腺癌专业委员会, 中华医学会肿瘤学分会乳腺肿瘤学组 . 中国抗癌协会乳腺癌诊治指南与规范(2024年版) [J ] . 中国癌症杂志 , 2023 , 33 ( 12 ): 1092 - 1187 . DOI: 10.19401/j.cnki.1007-3639.2023.12.004 http://doi.org/10.19401/j.cnki.1007-3639.2023.12.004

The Society of Breast Cancer China Anti-Cancer Association, Breast Oncology Group of the Oncology Branch of the Chinese Medical Association . Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2024 edition) [J ] . Chin Oncol , 2023 , 33 ( 12 ): 1092 - 1187 . DOI: 10.19401/j.cnki.1007-3639.2023.12.004 http://doi.org/10.19401/j.cnki.1007-3639.2023.12.004

GIAQUINTO A N , SUNG H , MILLER K D , et al . Breast cancer statistics, 2022 [J ] . CA A Cancer J Clinicians , 2022 , 72 ( 6 ): 524 - 541 .

FOULKES W D , SMITH I E , REIS-FILHO J S . Triple-negative breast cancer [J ] . N Engl J Med , 2010 , 363 ( 20 ): 1938 - 1948 .

YIN L , DUAN J J , BIAN X W , et al . Triple-negative breast cancer molecular subtyping and treatment progress [J ] . Breast Cancer Res , 2020 , 22 ( 1 ): 61 . DOI: 10.1186/s13058-020-01296-5 http://doi.org/10.1186/s13058-020-01296-5

HAN Y Q , WANG J Y , SUN T , et al . Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer [J ] . Signal Transduct Target Ther , 2023 , 8 : 429 .

CHEN X , MA C N , LI Y M , et al . COL5A1 promotes triple-negative breast cancer progression by activating tumor cell-macrophage crosstalk [J ] . Oncogene , 2024 , 43 : 1742 - 1756 . DOI: 10.1038/s41388-024-03030-3 http://doi.org/10.1038/s41388-024-03030-3

XU G F , HUANG R , WUMAIER R , et al . Proteomic profiling of serum extracellular vesicles identifies diagnostic signatures and therapeutic targets in breast cancer [J ] . Cancer Res , 2024 , 84 ( 19 ): 3267 - 3285 .

JIANG Y Z , MA D , JIN X , et al . Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities [J ] . Nat Cancer , 2024 , 5 : 673 - 690 .

PAN H C , GRAY R , BRAYBROOKE J , et al . 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years [J ] . N Engl J Med , 2017 , 377 ( 19 ): 1836 - 1846 .

ZHANG K M , ZHAO D C , LI Z Y , et al . Inactivated cGAS-STING signaling facilitates endocrine resistance by forming a positive feedback loop with AKT kinase in ER + HER2 - breast cancer [J ] . Adv Sci , 2024 , 11 ( 35 ): 2403592 .

LI K , SHU D , LI H , et al . SMAD4 depletion contributes to endocrine resistance by integrating ER and ERBB signaling in HR + HER2 - breast cancer [J ] . Cell Death Dis , 2024 , 15 ( 6 ): 444 .

CHEN X , DING J C , HU G S , et al . Estrogen-induced LncRNA, LINC02568, promotes estrogen receptor-positive breast cancer development and drug resistance through both in trans and in cis mechanisms [J ] . Adv Sci (Weinh) , 2023 , 10 ( 25 ): e2206663 .

SPRING L M , WANDER S A , ANDRE F , et al . Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future [J ] . Lancet , 2020 , 395 ( 10226 ): 817 - 827 . DOI: S0140-6736(20)30165-3 http://doi.org/S0140-6736(20)30165-3

QUAN C T , WU Z J , XIONG J , et al . Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation [J ] . Exp Hematol Oncol , 2023 , 12 ( 1 ): 100 . DOI: 10.1186/s40164-023-00462-7 http://doi.org/10.1186/s40164-023-00462-7

CAI Z J , SHI Q F , LI Y D , et al . LncRNA EILA promotes CDK4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein [J ] . Sci Adv , 2023 , 9 ( 40 ): eadi3821.

SWAIN S M , SHASTRY M , HAMILTON E . Targeting HER2-positive breast cancer: advances and future directions [J ] . Nat Rev Drug Discov , 2023 , 22 ( 2 ): 101 - 126 .

LI Y H , HUANG M , WANG M E , et al . Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite [J ] . Cancer Cell , 2024 , 42 ( 6 ): 985 - 1002 .e18.

XING F , GAO H L , CHEN G L , et al . CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer [J ] . Mol Cancer , 2023 , 22 ( 1 ): 6 . DOI: 10.1186/s12943-023-01716-y http://doi.org/10.1186/s12943-023-01716-y

DUAN N J , HUA Y J , YAN X Q , et al . Unveiling alterations of epigenetic modifications and chromatin architecture leading to lipid metabolic reprogramming during the evolutionary trastuzumab adaptation of HER2-positive breast cancer [J ] . Adv Sci (Weinh) , 2024 , 11 ( 18 ): e2309424.

YATES L R , KNAPPSKOG S , WEDGE D , et al . Genomic evolution of breast cancer metastasis and relapse [J ] . Cancer Cell , 2017 , 32 ( 2 ): 169 - 184 .e7. DOI: S1535-6108(17)30297-0 http://doi.org/S1535-6108(17)30297-0

SCHLAM I , SWAIN S M . HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now [J ] . NPJ Breast Cancer , 2021 , 7 ( 1 ): 56 . DOI: 10.1038/s41523-021-00265-1 http://doi.org/10.1038/s41523-021-00265-1

ZHANG H Y , ZHANG L L , HE Y N , et al . PI3K PROTAC overcomes the lapatinib resistance in PIK3CA -mutant HER2 positive breast cancer [J ] . Cancer Lett , 2024 , 598 : 217112 .

GUO L W , LI X G , YANG Y S , et al . Large-scale genomic sequencing reveals adaptive opportunity of targeting mutated-PI3Kα in early and advanced HER2-positive breast cancer [J ] . Clin Transl Med , 2021 , 11 ( 11 ): e589 .

WANG J N , XU B H . Targeted therapeutic options and future perspectives for HER2-positive breast cancer [J ] . Signal Transduct Target Ther , 2019 , 4 : 34 .

LIU X X , ZHANG X , SHAO Z Y , et al . Pyrotinib and chrysin synergistically potentiate autophagy in HER2-positive breast cancer [J ] . Signal Transduct Target Ther , 2023 , 8 : 463 .

ZHU X Z , CHEN L , HUANG B H , et al . Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer [J ] . J Exp Clin Cancer Res , 2021 , 40 ( 1 ): 122 . DOI: 10.1186/s13046-021-01930-w http://doi.org/10.1186/s13046-021-01930-w

DERAKHSHAN F , REIS-FILHO J S . Pathogenesis of triple-negative breast cancer [J ] . Annu Rev Pathol , 2022 , 17 : 181 - 204 . DOI: 10.1146/annurev-pathol-042420-093238 http://doi.org/10.1146/annurev-pathol-042420-093238

YAO L T , HAO Q , WANG M Z , et al . KLHL29-mediated DDX3X degradation promotes chemosensitivity by abrogating cell cycle checkpoint in triple-negative breast cancer [J ] . Oncogene , 2023 , 42 : 3514 - 3528 . DOI: 10.1038/s41388-023-02858-5 http://doi.org/10.1038/s41388-023-02858-5

DIECI M V , GUARNERI V , TOSI A , et al . Neoadjuvant chemotherapy and immunotherapy in luminal B-like breast cancer: results of the phase Ⅱ GIADA trial [J ] . Clin Cancer Res , 2022 , 28 ( 2 ): 308 - 317 .

CAI Y W , LIU C C , ZHANG Y W , et al . MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor-positive HER2-negative breast cancer [J ] . J Clin Invest , 2024 , 135 ( 2 ): e183656 .

LI X C , CHEN G D , WANG F C , et al . Oncogenic PIK3CA recruits myeloid-derived suppressor cells to shape the immunosuppressive tumour microenvironment in luminal breast cancer through the 5-lipoxygenase-dependent arachidonic acid pathway [J ] . Clin Transl Med , 2023 , 13 ( 11 ): e1483 . DOI: 10.1002/ctm2.1483 http://doi.org/10.1002/ctm2.1483

ADAMS S , GATTI-MAYS M E , KALINSKY K , et al . Current landscape of immunotherapy in breast cancer: a review [J ] . JAMA Oncol , 2019 , 5 ( 8 ): 1205 - 1214 . DOI: 10.1001/jamaoncol.2018.7147 http://doi.org/10.1001/jamaoncol.2018.7147

YU B , LUO F , SUN B W , et al . KAT6A acetylation of SMAD3 regulates myeloid-derived suppressor cell recruitment, metastasis, and immunotherapy in triple-negative breast cancer [J ] . Adv Sci (Weinh) , 2021 , 8 ( 20 ): e2100014 .

WANG H , RONG X Y , ZHAO G , et al . The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer [J ] . Cell Metab , 2022 , 34 ( 4 ): 581 - 594 .e8. DOI: 10.1016/j.cmet.2022.02.010 http://doi.org/10.1016/j.cmet.2022.02.010

XIA J , ZHANG L X , PENG X , et al . IL1R2 blockade alleviates immunosuppression and potentiates anti-pd-1 efficacy in triple-negative breast cancer [J ] . Cancer Res , 2024 , 84 ( 14 ): 2282 - 2296 .

VITALE I , SHEMA E , LOI S , et al . Intratumoral heterogeneity in cancer progression and response to immunotherapy [J ] . Nat Med , 2021 , 27 ( 2 ): 212 - 224 . DOI: 10.1038/s41591-021-01233-9 http://doi.org/10.1038/s41591-021-01233-9

GE L P , JIN X , MA D , et al . ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer [J ] . Cell Res , 2024 , 34 ( 1 ): 58 - 75 .

JIANG Y Z , MA D , SUO C , et al . Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies [J ] . Cancer Cell , 2019 , 35 ( 3 ): 428 - 440 .e5.

JIN X , ZHOU Y F , MA D , et al . Molecular classification of hormone receptor-positive HER2-negative breast cancer [J ] . Nat Genet , 2023 , 55 : 1696 - 1708 . DOI: 10.1038/s41588-023-01507-7 http://doi.org/10.1038/s41588-023-01507-7

LI Y W , DAI L J , WU X R , et al . Molecular characterization and classification of HER2-positive breast cancer inform tailored therapeutic strategies [J ] . Cancer Res , 2024 , 84 ( 21 ): 3669 - 3683 .

XIAO Y , MA D , YANG Y S , et al . Comprehensive metabolomics expands precision medicine for triple-negative breast cancer [J ] . Cell Res , 2022 , 32 ( 5 ): 477 - 490 . DOI: 10.1038/s41422-022-00614-0 http://doi.org/10.1038/s41422-022-00614-0

GONG Y , JI P , YANG Y S , et al . Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets [J ] . Cell Metab , 2021 , 33 ( 1 ): 51 - 64 .e9. DOI: 10.1016/j.cmet.2020.10.012 http://doi.org/10.1016/j.cmet.2020.10.012

YANG F , XIAO Y , DING J H , et al . Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy [J ] . Cell Metab , 2023 , 35 ( 1 ): 84 - 100 .e8.

SU G H , XIAO Y , YOU C , et al . Radiogenomic-based multiomic analysis reveals imaging intratumor heterogeneity phenotypes and therapeutic targets [J ] . Sci Adv , 2023 , 9 ( 40 ): eadf0837 .

DING J H , XIAO Y , YANG F , et al . Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer [J ] . Sci Transl Med , 2024 , 16 ( 728 ): eadg7740 .

MEHTA S , ZHANG J . Liquid-liquid phase separation drives cellular function and dysfunction in cancer [J ] . Nat Rev Cancer , 2022 , 22 ( 4 ): 239 - 252 . DOI: 10.1038/s41568-022-00444-7 http://doi.org/10.1038/s41568-022-00444-7

LU B , QIU R , WEI J T , et al . Phase separation of phospho-HDAC6 drives aberrant chromatin architecture in triple-negative breast cancer [J ] . Nat Cancer , 2024 , 5 : 1622 - 1640 .

SUN Y J , SUN Y Y , YUE S C , et al . Histone deacetylase inhibitors in cancer therapy [J ] . Curr Top Med Chem , 2018 , 18 ( 28 ): 2420 - 2428 . DOI: 10.2174/1568026619666181210152115 http://doi.org/10.2174/1568026619666181210152115

HU Z L , WEI F , SU Y , et al . Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression [J ] . Signal Transduct Target Ther , 2023 , 8 ( 1 ): 11 .

LIU J Z , ZHAI M , CHEN Y Y , et al . Acetylation-dependent deubiquitinase USP26 stabilizes BAG3 to promote breast cancer progression [J ] . Cancer Lett , 2024 , 597 : 217005 .

PETROWSKY H , FRITSCH R , GUCKENBERGER M , et al . Modern therapeutic approaches for the treatment of malignant liver tumours [J ] . Nat Rev Gastroenterol Hepatol , 2020 , 17 ( 12 ): 755 - 772 .

TANG X Y , MAO X R , LING P W , et al . Glycolysis inhibition induces anti-tumor central memory CD8 + T cell differentiation upon combination with microwave ablation therapy [J ] . Nat Commun , 2024 , 15 : 4665 .

LIU C C , CHEN L , CAI Y W , et al . Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer [J ] . Cell Rep Med , 2024 , 5 ( 2 ): 101396 .

LIU D , LU Q , WANG X , et al . LSECtin on tumor-associated macrophages enhances breast cancer stemness via interaction with its receptor BTN3A3 [J ] . Cell Res , 2019 , 29 ( 5 ): 365 - 378 . DOI: 10.1038/s41422-019-0155-6 http://doi.org/10.1038/s41422-019-0155-6

ZHENG G X , GUO Z Y , LI W M , et al . Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab [J ] . Signal Transduct Target Ther , 2021 , 6 ( 1 ): 236 .

DU R X , ZHANG X M , LU X Y , et al . PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity [J ] . Drug Resist Updat , 2023 , 68 : 100947 .

LIU X W , LU Y W , HUANG J Y , et al . CD16 + fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition [J ] . Cancer Cell , 2022 , 40 ( 11 ): 1341 - 1357 .e13.

SIEGEL R L , MILLER K D , FUCHS H E , et al . Cancer statistics, 2021 [J ] . CA A Cancer J Clin , 2021 , 71 ( 1 ): 7 - 33 .

BAI H R , LIU X Q , LIN M Z , et al . Progressive senescence programs induce intrinsic vulnerability to aging-related female breast cancer [J ] . Nat Commun , 2024 , 15 : 5154 . DOI: 10.1038/s41467-024-49106-2 http://doi.org/10.1038/s41467-024-49106-2

ZHU Y X , JIA H R , GAO G , et al . Mitochondria-acting nanomicelles for destruction of cancer cells via excessive mitophagy/autophagy-driven lethal energy depletion and phototherapy [J ] . Biomaterials , 2020 , 232 : 119668 .

GUO Y , CUI Y Q , LI Y Y , et al . Cytoplasmic YAP1-mediated ESCRT-Ⅲ assembly promotes autophagic cell death and is ubiquitinated by NEDD4L in breast cancer [J ] . Cancer Commun (Lond) , 2023 , 43 ( 5 ): 582 - 612 .

DIXON S J , LEMBERG K M , LAMPRECHT M R , et al . Ferroptosis: an iron-dependent form of nonapoptotic cell death [J ] . Cell , 2012 , 149 ( 5 ): 1060 - 1072 . DOI: 10.1016/j.cell.2012.03.042 http://doi.org/10.1016/j.cell.2012.03.042

DING Y H , CHEN X P , LIU C , et al . Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells [J ] . J Hematol Oncol , 2021 , 14 ( 1 ): 19 .

OUYANG B S , SHAN C H , SHEN S , et al . AI-powered omics-based drug pair discovery for pyroptosis therapy targeting triple-negative breast cancer [J ] . Nat Commun , 2024 , 15 ( 1 ): 7560 . DOI: 10.1038/s41467-024-51980-9 http://doi.org/10.1038/s41467-024-51980-9

ZHAO S , CHEN D P , FU T , et al . Single-cell morphological and topological atlas reveals the ecosystem diversity of human breast cancer [J ] . Nat Commun , 2023 , 14 ( 1 ): 6796 . DOI: 10.1038/s41467-023-42504-y http://doi.org/10.1038/s41467-023-42504-y

ZHANG S W , YANG B , YANG H P , et al . Potential rapid intraoperative cancer diagnosis using dynamic full-field optical coherence tomography and deep learning: a prospective cohort study in breast cancer patients [J ] . Sci Bull (Beijing) , 2024 , 69 ( 11 ): 1748 - 1756 .

ZHAO L , CHANG F , TONG Y , et al . A multifunctional bimetallic nanoplatform for synergic local hyperthermia and chemotherapy targeting HER2-positive breast cancer [J ] . Adv Sci (Weinh) , 2024 , 11 ( 16 ): e2308316 .

LI K , LIN C C , LI M H , et al . Multienzyme-like reactivity cooperatively impairs glutathione peroxidase 4 and ferroptosis suppressor protein 1 pathways in triple-negative breast cancer for sensitized ferroptosis therapy [J ] . ACS Nano , 2022 , 16 ( 2 ): 2381 - 2398 . DOI: 10.1021/acsnano.1c08664 http://doi.org/10.1021/acsnano.1c08664

JI X Y , GUO D X , MA J , et al . Epigenetic remodeling hydrogel patches for multidrug-resistant triple-negative breast cancer [J ] . Adv Mater , 2021 , 33 ( 18 ): e2100949 .

HUANG D , ZHU X F , YE S Y , et al . Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides [J ] . Nature , 2024 , 625 : 593 - 602 .

CAI Z J , WANG J R , LI Y D , et al . Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors [J ] . Sci China Life Sci , 2023 , 66 ( 1 ): 94 - 109 .

SONG X X , ZHOU Z , LI H C , et al . Pharmacologic suppression of B7-H4 glycosylation restores antitumor immunity in immune-cold breast cancers [J ] . Cancer Discov , 2020 , 10 ( 12 ): 1872 - 1893 . DOI: 10.1158/2159-8290.CD-20-0402 http://doi.org/10.1158/2159-8290.CD-20-0402

ZHANG Y , CHEN H , MO H , et al . Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer [J ] . Cancer Cell , 2021 , 39 ( 12 ): 1578 - 1593 .e8. DOI: 10.1016/j.ccell.2021.09.010 http://doi.org/10.1016/j.ccell.2021.09.010

LI H Y , YANG P H , WANG J H , et al . HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk [J ] . J Hematol Oncol , 2022 , 15 ( 1 ): 2 .

LUO F , ZHANG M D , SUN B W , et al . LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling [J ] . Mol Cancer , 2024 , 23 ( 1 ): 60 . DOI: 10.1186/s12943-024-01975-3 http://doi.org/10.1186/s12943-024-01975-3

JIANG L L , REN L L , CHEN H , et al . NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer [J ] . Cell Death Dis , 2020 , 11 ( 7 ): 547 . DOI: 10.1038/s41419-020-02753-x http://doi.org/10.1038/s41419-020-02753-x

LING Y , LIANG G H , LIN Q , et al . circCDYL2 promotes trastuzu mab resistance via sustaining HER2 downstream signaling in breast cancer [J ] . Mol Cancer , 2022 , 21 ( 1 ): 8 .

浏览量

2484

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

转移性结直肠癌三线治疗的研究现状及进展

乳腺癌免疫检查点抑制剂治疗的研究进展与探索方向

肿瘤相关中性粒细胞在乳腺癌发生、发展中的作用研究进展

2022年中国乳腺癌重要临床试验成果及最新进展

在乳腺癌局部精准治疗中的新进展：联合免疫治疗未来可期